Viewing data from:

NUVARING

NDA

ETHINYL ESTRADIOL; ETONOGESTREL | N021187 | ORGANON USA LLC A SUB OF ORGANON AND CO

1 strength0 unique patents0 unique exclusivities

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

1 case on OB patents (1 active) from PACER

Case	Court	Filed	Status	Judge
MERCK SHARP & DOHME B.V. et al v. XIROMED PHARMA ESPAA, S.L. et al 2:2025cv02254 2 patentsANDA 217698etonogestrel	D.N.J.	2025-04-02	Active	—

Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Medicare Part D Spending

CMS annual spending data for Nuvaring (2023)

Total Spending

$197K

Total Claims

544

Beneficiaries

164

Avg Cost/Unit

$164.75

Spending Trend

$59K(2021)→$233K(2022)→$197K(2023)

YoY Change:+1.4%

5yr CAGR:+0.7%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

Approval Letters

19 letters from Drugs@FDA

Source: Drugs@FDA application documents.

Products (1)

#001 — 0.015MG/24HR;0.12MG/24HR

RLDAB

0 patents0 exclusivities▴

RING;VAGINAL | Approved: Oct 3, 2001

No patent or exclusivity listings for this strength.